Roka BioScience negotiates $6.75 million at-the-market equity offering

Deal arranged with Cantor Fitzgerald; proceeds fund corporate purposes

By Devika Patel

Knoxville, Tenn., Oct. 30 – Roka BioScience, Inc. arranged a $6.75 million at-the-market equity offering with agent Cantor Fitzgerald & Co. on Oct. 30, according to an 8-K and prospectus supplement filed Friday with the Securities and Exchange Commission.

Cantor will be paid a 3% commission.

Proceeds will be used for working capital and general corporate purposes.

The molecular diagnostics company is based in Warren, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.